EP4284328A2 - Reinigungszusammensetzung mit verbesserter abscheidung von salicylsäure zur aknebehandlung - Google Patents

Reinigungszusammensetzung mit verbesserter abscheidung von salicylsäure zur aknebehandlung

Info

Publication number
EP4284328A2
EP4284328A2 EP22702052.6A EP22702052A EP4284328A2 EP 4284328 A2 EP4284328 A2 EP 4284328A2 EP 22702052 A EP22702052 A EP 22702052A EP 4284328 A2 EP4284328 A2 EP 4284328A2
Authority
EP
European Patent Office
Prior art keywords
composition
cationic
acid
cosmetic composition
gum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22702052.6A
Other languages
English (en)
French (fr)
Inventor
Siliu Tan
Ryuji Hara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/162,392 external-priority patent/US20220249341A1/en
Priority claimed from FR2104695A external-priority patent/FR3122576B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP4284328A2 publication Critical patent/EP4284328A2/de
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/042Gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/736Chitin; Chitosan; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/737Galactomannans, e.g. guar; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Definitions

  • the acne treatment active comprising at least one beta hydroxy acid is present in the composition in a range from about 0.1% to about 2%, by weight, based on the total weight of the composition.
  • the at least one beta hydroxy acid is salicylic acid.
  • each of the at least one surfactant is present in an amount that ranges from about 0.1% to about 20% by weight.
  • the composition includes a blend of humectants, antimicrobials, preservatives, actives, pH adjusters and chelating agents comprising C12-15 alkyl lactate and C12-15 alcohols, citric acid, trisodium ethylenediamine disuccinate, phenoxyethanol, caprylyl glycol, chlorphenesin, ammonium polyacryloyldimethyl taurate, propylene glycol and PEG-55 propylene glycol oleate, and kaolin.
  • stable disposition of an acne treatment active means deposition, for example, beta hydroxy acid, on the skin that is resistant to removal by rinsing and/or use of a cleansing apparatus, such as a cleansing brush.
  • cationic nature-based polymer selected from polysaccharides may be chosen from polysaccharides that include chitosan, chitin, starches, alginates, celluloses, galactomannans such as guar gums, particularly cationic derivatives thereof, and combinations thereof.
  • the at least one cationic nature-based polymer selected from polysaccharides may be chosen from chitosan, chitosan derivatives, chitin, starch, starch derivatives, cellulose (for example, but not limited to, ethylcellulose, nitrocellulose, hemicellulose, and hemicellulose derivatives), alginates, including but not limited to, sodium alginate, and combinations thereof.
  • cationic nature-based polymer selected from polysaccharides may be chosen from one or more of methylcelluloses, hydroxyalkylcelluloses, ethylhydroxyethylcelluloses and carboxymethylcelluloses, mannans, xylans, lignins, arabans, galacturonans, alginate-based compounds, chitin, glucuronoxylans, arabinoxylans, xyloglucans, glucomannans, fructosans such as inulin, pectic acids and pectins, arabinogalactans, agars, glycosaminoglycans, gum arabics, tragacanth gums, ghatti gums, karaya gums, locust bean gums, biopolysaccharide gums of microbial origin such as scleroglucan or xanthan gums, mucopolysaccharides, chondroitin sulfates
  • POLYMER by the company Nalco (Lubrizol) (INCI name: Polyquaternium-22); the copolymer of methacrylamidopropyltrimonium chloride, of acrylic acid and or methyl acrylate, sold under the name MERQUAT 2001 POLYMER OR MERQUAT 2001N POLYMER by the company Nalco (Lubrizol) (INCI name: Polyquaternium-47); the acrylamide/dimethyldiallylammonium chloride/acrylic acid terpolymer sold under the name MERQUAT 3330DRY POLYMER or MERQUAT 3330PR POLYMER or MERQUAT 3331PR POLYMER or MERQUAT 3940 POLYMER or MERQUAT PLUS 3330
  • the composition includes the combination of surfactants that comprise Coco Betaine, Decyl Glucoside, PEG-150 Pentaerythrityl Tetrastearate, PEG-6 Caprylic/Capric Glycerides and Sodium Laureth Sulfate.
  • surfactants that comprise Coco Betaine, Decyl Glucoside, PEG-150 Pentaerythrityl Tetrastearate, PEG-6 Caprylic/Capric Glycerides and Sodium Laureth Sulfate.
  • the at least one surfactant may be selected from the group consisting of PEG-100 Stearate; PEG-20 Stearate and other esters of PolyfEthylene Glycol); Sucrose Stearate and other emulsifiers based on sugar esters; Glyceryl Stearate and other glycerol esters; Disodium Ethylene Dicocamide PEG-15 Disulfate; Sodium Steroyl Glutamate and other fatty amides; Steareth-100 and other fatty ethers sodium C14-16 olefin sulfonate, disodium laureth sulfosuccinate (and) sodium lauryl sulfoacetate, sodium lauroyl sarcosinate, sodium methyl cocoyl taurate, sodium methyl lauroyl taurate, sodium cocoyl alaninate, sodium cocoyl isethionate, cocamidopropyl hydroxysultaine, cocamidopropyl be
  • water is present, by weight, based on the total weight of the composition, from about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 80, 85, to about 90 weight percent, including increments and all ranges and subranges therein and there between.
  • any one of or a combination of humectant, when present, may be present, by weight, based on the total weight of the composition, is from about 1, 2, 3, 4, 5, 6, 7, 8, 9, to about 10 weight percent, including increments and ranges therein and there between.
  • BIOSKIN samples of about 2 in by 2 inches were provides. Each bioskin sample was treated with one of an inventive, example and comparative composition by application of about 0.5 g of the tested composition with a cleansing brush (Clarisonic (TM) brush). Cleansed samples were soaked in water for about 30 seconds, then massaged using the cleansing brush for about one minute. The samples were then rinsed under water at forty degrees C then air dried for about an hour. Samples were then soaked in a solution of iron chloride (0.01% FeCIs) for about an hour then air dried overnight.
  • TM cleansing brush
  • the relative increase in deposition of beta hydroxy acid, for example, salicylic acid, obtained using an inventive composition containing a cationic polymer is greater than what is obtained in the absence of cationic polymer in a range from about 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123,

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22702052.6A 2021-01-29 2022-01-28 Reinigungszusammensetzung mit verbesserter abscheidung von salicylsäure zur aknebehandlung Pending EP4284328A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/162,392 US20220249341A1 (en) 2021-01-29 2021-01-29 Cleansing composition providing enhanced deposition of salicylic acid for acne treatment
FR2104695A FR3122576B1 (fr) 2021-05-04 2021-05-04 Composition nettoyante fournissant un dépôt amélioré d’acide salicylique pour le traitement de l’acné
PCT/IB2022/050780 WO2022162620A2 (en) 2021-01-29 2022-01-28 Cleansing composition providing enhanced deposition of salicylic acid for acne treatment

Publications (1)

Publication Number Publication Date
EP4284328A2 true EP4284328A2 (de) 2023-12-06

Family

ID=80119326

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22702052.6A Pending EP4284328A2 (de) 2021-01-29 2022-01-28 Reinigungszusammensetzung mit verbesserter abscheidung von salicylsäure zur aknebehandlung

Country Status (2)

Country Link
EP (1) EP4284328A2 (de)
WO (1) WO2022162620A2 (de)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
JP2006249001A (ja) * 2005-03-11 2006-09-21 Kose Corp ゲル状ニキビ用化粧料
WO2013159865A1 (de) * 2012-04-25 2013-10-31 Merck Patent Gmbh Verwendung von dicyclohexylmethanolderivaten mit antimikrobiellen eigenschaften
CN104622710B (zh) * 2013-11-15 2020-06-02 上海家化联合股份有限公司 水杨酸和脱乙酰壳多糖复配组合物的制备与应用
CN105769698B (zh) * 2016-04-14 2019-08-23 曼秀雷敦(中国)药业有限公司 一种不含防腐剂的化妆品组合物及其应用
CN106726690B (zh) * 2016-12-27 2020-08-11 广东迪美新材料科技有限公司 一种水溶性水杨酸微球及其制备方法
CN106726989A (zh) * 2016-12-28 2017-05-31 广州市聚吉科绿色化学共性技术研究院有限公司 一种从荷兰豆中提取荷兰豆提取物的方法及其应用
CN110101649A (zh) * 2019-06-18 2019-08-09 欧诗漫生物股份有限公司 化妆品组合物及其应用、应用其的产品及制备方法
US20210093724A1 (en) * 2019-09-30 2021-04-01 Concept Matrix Solutions Topical anti-acne composition

Also Published As

Publication number Publication date
WO2022162620A2 (en) 2022-08-04
WO2022162620A3 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
EP3116986B1 (de) Handdesinfizierer mit verbesserter ästhetik und hautpflege zur förderung der einhaltung von handhygienerichtlinien
FR2966364A1 (fr) Composition cosmetique comprenant de l'aloe vera et un derive d'acide isethionique
DE102015225004A1 (de) Tensid-haltige Reinigungsmittel mit mindestens drei unterschiedlichen Konservierungsmitteln
WO2009014327A2 (en) Liquid body cleanser composition
GB2603231A (en) Natural cosmetic cleanser
EP4284328A2 (de) Reinigungszusammensetzung mit verbesserter abscheidung von salicylsäure zur aknebehandlung
US20220249341A1 (en) Cleansing composition providing enhanced deposition of salicylic acid for acne treatment
EP4392000A1 (de) Sulfatfreie reinigungszusammensetzung mit hoher salicylsäureablagerung
WO2023026167A1 (en) Sulfate-free cleansing composition that confers high salicylic acid deposition
US20230083646A1 (en) Sulfate-free cleansing composition that confers high salicylic acid deposition
EP2563479A2 (de) Mikriobiologisch stabile anwendungsfreundliche zubereitung mit verdickern
EP4126252B1 (de) Zusammensetzungen mit natürlichen konservierungsmitteln
EP4203902A1 (de) Haarbehandlungsmittel mit antischuppenwirkung
WO2021041312A1 (en) Silicone-free, low-friction cleanser with high-foaming properties
DE102016225962A1 (de) Haarbehandlungsmittel mit hydrophoben pyrogenen Kieselsäuren
US20220249342A1 (en) Cosmetic cleansing compositions with viscosity modifiers and oils
WO2023193967A1 (de) Haarbehandlungsmittel mit antischuppenwirkung
CN116669692A (zh) 包含甘氨酸盐表面活性剂、多元醇和含有烷基葡糖苷的非离子表面活性剂的个人护理组合物
EP4312963A1 (de) Gelstabilisierte o/w-emulsion mit alpha-arbutin und azelainsäuredispersion
US20220273543A1 (en) Gel stabilized o/w emulsion with alpha-arbutin and azelaic acid dispersion
FR3131842A1 (fr) Composition comprenant des particules complexes polyioniques à base d'acide hyaluronique et un tensioactif
WO2022072585A1 (en) Cosmetic compositions comprising an antimicrobial system with reduced eye irritation or discomfort
DE102014222569A1 (de) Duschlotionen II
WO2023174769A1 (en) A cleansing composition
WO2023193962A1 (de) Antischuppenshampoo

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230712

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)